Compare Dishman Pharma with TTK HEALTHCARE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs TTK HEALTHCARE - Comparison Results

DISHMAN PHARMA     Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA TTK HEALTHCARE DISHMAN PHARMA/
TTK HEALTHCARE
 
P/E (TTM) x 25.1 69.9 35.9% View Chart
P/BV x 3.3 1.7 191.7% View Chart
Dividend Yield % 0.7 0.9 75.1%  

Financials

 DISHMAN PHARMA   TTK HEALTHCARE
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
TTK HEALTHCARE
Mar-19
DISHMAN PHARMA/
TTK HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs3741,215 30.8%   
Low Rs129610 21.1%   
Sales per share (Unadj.) Rs197.8444.4 44.5%  
Earnings per share (Unadj.) Rs21.217.2 123.0%  
Cash flow per share (Unadj.) Rs34.727.6 125.7%  
Dividends per share (Unadj.) Rs2.005.00 40.0%  
Dividend yield (eoy) %0.80.5 145.1%  
Book value per share (Unadj.) Rs179.9177.9 101.1%  
Shares outstanding (eoy) m80.6914.13 571.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.32.1 62.0%   
Avg P/E ratio x11.952.9 22.4%  
P/CF ratio (eoy) x7.233.0 21.9%  
Price / Book Value ratio x1.45.1 27.3%  
Dividend payout %9.429.0 32.5%   
Avg Mkt Cap Rs m20,30612,894 157.5%   
No. of employees `0000.82.3 35.9%   
Total wages/salary Rs m5,3551,307 409.7%   
Avg. sales/employee Rs Th19,252.72,715.7 708.9%   
Avg. wages/employee Rs Th6,459.5565.3 1,142.6%   
Avg. net profit/employee Rs Th2,064.1105.4 1,958.2%   
INCOME DATA
Net Sales Rs m15,9616,279 254.2%  
Other income Rs m26578 342.5%   
Total revenues Rs m16,2266,356 255.3%   
Gross profit Rs m4,103496 827.9%  
Depreciation Rs m1,091147 743.4%   
Interest Rs m94434 2,794.1%   
Profit before tax Rs m2,334393 594.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m624149 418.8%   
Profit after tax Rs m1,711244 702.1%  
Gross profit margin %25.77.9 325.7%  
Effective tax rate %26.737.9 70.5%   
Net profit margin %10.73.9 276.2%  
BALANCE SHEET DATA
Current assets Rs m11,0182,717 405.5%   
Current liabilities Rs m9,5171,571 605.9%   
Net working cap to sales %9.418.3 51.5%  
Current ratio x1.21.7 66.9%  
Inventory Days Days11032 343.6%  
Debtors Days Days3547 74.7%  
Net fixed assets Rs m16,304991 1,645.2%   
Share capital Rs m161141 114.2%   
"Free" reserves Rs m12,9072,373 543.9%   
Net worth Rs m14,5162,514 577.3%   
Long term debt Rs m4,1893 123,217.6%   
Total assets Rs m29,8054,158 716.8%  
Interest coverage x3.512.6 27.5%   
Debt to equity ratio x0.30 21,343.1%  
Sales to assets ratio x0.51.5 35.5%   
Return on assets %8.96.7 133.5%  
Return on equity %11.89.7 121.6%  
Return on capital %17.516.9 103.5%  
Exports to sales %24.83.6 691.1%   
Imports to sales %3.70.5 757.9%   
Exports (fob) Rs m3,956225 1,756.7%   
Imports (cif) Rs m59631 1,926.7%   
Fx inflow Rs m4,952225 2,198.7%   
Fx outflow Rs m69771 979.9%   
Net fx Rs m4,255154 2,761.2%   
CASH FLOW
From Operations Rs m2,786173 1,609.7%  
From Investments Rs m-1,52997 -1,584.4%  
From Financial Activity Rs m-941-307 306.2%  
Net Cashflow Rs m316-38 -839.3%  

Share Holding

Indian Promoters % 61.4 65.4 93.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 3.7 100.0%  
FIIs % 12.7 5.2 244.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 25.8 85.7%  
Shareholders   46,261 12,723 363.6%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   VENUS REMEDIES  NEULAND LABS  PIRAMAL ENTERPRISES  J.B.CHEMICALS  SHASUN PHARMA  

Compare DISHMAN PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Crucial Week Ahead for the Indian Stock Market(Momentum Moves)

The market scaled new life-time highs this week but it was the bears who took control. The benchmark indices, Sensex and Nifty ended mostly flat for the week but the momentum was in favour of the bears.

Related Views on News

TTK HEALTHCARE Announces Quarterly Results (3QFY20); Net Profit Down 8.3% (Quarterly Result Update)

Jan 30, 2020 | Updated on Jan 30, 2020

For the quarter ended December 2019, TTK HEALTHCARE has posted a net profit of Rs 45 m (down 8.3% YoY). Sales on the other hand came in at Rs 2 bn (up 11.2% YoY). Read on for a complete analysis of TTK HEALTHCARE's quarterly results.

TTK HEALTHCARE Announces Quarterly Results (1QFY20); Net Profit Down 53.8% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, TTK HEALTHCARE has posted a net profit of Rs 36 m (down 53.8% YoY). Sales on the other hand came in at Rs 2 bn (up 3.2% YoY). Read on for a complete analysis of TTK HEALTHCARE's quarterly results.

TTK HEALTHCARE 2018-19 Annual Report Analysis (Annual Result Update)

Jul 18, 2019 | Updated on Jul 18, 2019

Here's an analysis of the annual report of TTK HEALTHCARE for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of TTK HEALTHCARE. Also includes updates on the valuation of TTK HEALTHCARE.

TTK HEALTHCARE Announces Quarterly Results (4QFY19); Net Profit Down 38.0% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, TTK HEALTHCARE has posted a net profit of Rs 50 m (down 38.0% YoY). Sales on the other hand came in at Rs 1 bn (down 3.8% YoY). Read on for a complete analysis of TTK HEALTHCARE's quarterly results.

TTK HEALTHCARE 2017-18 Annual Report Analysis (Annual Result Update)

Mar 27, 2019 | Updated on Mar 27, 2019

Here's an analysis of the annual report of TTK HEALTHCARE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of TTK HEALTHCARE. Also includes updates on the valuation of TTK HEALTHCARE.

More Views on News

Most Popular

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

Time to Book Profits in Pharma Stocks(Fast Profits Daily)

Jan 15, 2021

In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.

A Rare Chance to Invest in Potential Multibaggers in 2021(Profit Hunter)

Jan 11, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

Smallcap Stocks: Your Best Bet for 2021 and Beyond(Profit Hunter)

Jan 15, 2021

The pandemic failed to thwart Richa's investing success formula for 2020.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 8-QTR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS